1. Home
  2. CACC vs DYN Comparison

CACC vs DYN Comparison

Compare CACC & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credit Acceptance Corporation

CACC

Credit Acceptance Corporation

HOLD

Current Price

$570.54

Market Cap

6.0B

Sector

Finance

ML Signal

HOLD

DYN

Dyne Therapeutics Inc.

HOLD

Current Price

$26.00

Market Cap

4.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CACC
DYN
Founded
1972
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
4.8B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
CACC
DYN
Price
$570.54
$26.00
Analyst Decision
Hold
Strong Buy
Analyst Count
2
14
Target Price
$505.00
$37.00
AVG Volume (30 Days)
110.4K
2.5M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
83.00
N/A
EPS
25.04
N/A
Revenue
$2,317,200,000.00
N/A
Revenue This Year
$91.73
N/A
Revenue Next Year
$3.58
N/A
P/E Ratio
$22.89
N/A
Revenue Growth
7.16
N/A
52 Week Low
$401.90
$11.65
52 Week High
$668.86
$27.31

Technical Indicators

Market Signals
Indicator
CACC
DYN
Relative Strength Index (RSI) 44.94 57.40
Support Level $535.20 $16.55
Resistance Level $621.52 $26.62
Average True Range (ATR) 18.61 1.11
MACD 0.31 -0.18
Stochastic Oscillator 34.54 57.23

Price Performance

Historical Comparison
CACC
DYN

About CACC Credit Acceptance Corporation

Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.

About DYN Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Share on Social Networks: